Can-Fite BioPharma (TASE:CANF) - Cotización, noticias y análisis

Resumen de acción CANF

Can-Fite BioPharma Ltd., empresa biofarmacéutica en fase clínica, desarrolla productos terapéuticos de moléculas pequeñas para el tratamiento del cáncer, las enfermedades inflamatorias del hígado y la disfunción eréctil.

Acerca de la empresa

CANF fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($785K)

Se prevé que los beneficios disminuyan una media de 15.3% al año durante los próximos 3 años.

Tiene menos de 1 año de cash runway

Los accionistas han sido diluidos en el último año

+ 2 riesgos adicionales

Competidores de Can-Fite BioPharma Ltd.

Clal Biotechnology Industries

TASE:CBI

₪70.6m

Evogene

TASE:EVGN

₪122.1m

Kamada

TASE:KMDA

₪1.1b

Univo Pharmaceuticals

TASE:UNVO

₪2.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Can-Fite BioPharma
Historical stock prices
Current Share Price	₪0.026
52 Week High	₪0.041
52 Week Low	₪0.021
Beta	0.91
1 Month Change	-3.70%
3 Month Change	4.00%
1 Year Change	18.18%
3 Year Change	-89.47%
5 Year Change	-97.39%
Change since IPO	-99.92%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	CANF	IL Biotechs	Mercado IL
7D	-3.7%	-3.0%	-0.7%
1Y	18.2%	2.2%	10.4%

Rentabilidad vs. Industria: CANF superó al sector IL Biotechs , que obtuvo un rendimiento del 5.2% el año pasado.

Rentabilidad vs. Mercado: CANF superó al mercado IL, que obtuvo un rendimiento del 10.4% el año pasado.

Volatilidad de los precios

Is CANF's price volatile compared to industry and market?
CANF volatility
CANF Average Weekly Movement	4.8%
Biotechs Industry Average Movement	8.1%
Market Average Movement	4.4%
10% most volatile stocks in IL Market	8.4%
10% least volatile stocks in IL Market	3.1%

Precio estable de las acciones: CANF no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CANF (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1994	8	Motti Farbstein	www.canfite.com

Can-Fite BioPharma Ltd., una empresa biofarmacéutica en fase clínica, desarrolla productos terapéuticos de moléculas pequeñas para el tratamiento del cáncer, las enfermedades inflamatorias del hígado y la disfunción eréctil. El principal candidato a fármaco de la empresa es Piclidenoson, que ha finalizado el ensayo clínico de fase III para el tratamiento de la psoriasis; y el ensayo clínico de fase II para el tratamiento de COVID-19. También desarrolla Namodenoson, que está en fase III de ensayo clínico para el tratamiento del carcinoma hepatocelular, así como en fase IIb para el tratamiento de la esteatohepatitis no alcohólica; y CF602, que está en ensayo preclínico para el tratamiento de la disfunción eréctil.

Resumen de fundamentos de Can-Fite BioPharma Ltd.

¿Cómo se comparan los beneficios e ingresos de Can-Fite BioPharma con su capitalización de mercado?
Estadísticas fundamentales de CANF
Capitalización bursátil	₪38.93m
Beneficios(TTM)	-₪28.97m
Ingresos (TTM)	₪2.82m

13.8x

Ratio precio-ventas (PS)

-1.3x

Ratio precio-beneficio (PE)

¿Está CANF sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CANF
Ingresos	US$743.00k
Coste de los ingresos	US$0
Beneficio bruto	US$743.00k
Otros gastos	US$8.38m
Beneficios	-US$7.63m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.0051
Margen bruto	100.00%
Margen de beneficio neto	-1,027.46%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado CANF a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CANF

Recompensas

Análisis de riesgos

Competidores de Can-Fite BioPharma Ltd.

TASE:CBI

₪70.6m

TASE:EVGN

₪122.1m

TASE:KMDA

₪1.1b

TASE:UNVO

₪2.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Recent updates

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020)

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

No longer forecast to breakeven

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson